Unfortunately, recent results from phase III clinical trials showed a non-significant increase in patient survival in patients diagnosed with glioblastoma and methylated MGMT (O6-methylguanine–DNA methyltransferase) gene promoter. Here, MGMT is linked to glioblastoma.